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Objective(s): The reuse of disposable devices is a potential source of significant 
cost savings to hospitals. Venous and arterial perfusion cannulas under new 
and reused conditions were selected to identify the clinical, safety, technical, 
logistic, and economic issues that must be addressed to realize these savings. 
Methods: Single- and dual-stage venous and arterial cannulas from two 
manufacturers were tested when new, after initial clinical use, and after a 
single clinical use plus up to nine simulated reuses. Reuse was simulated by 
end-to-end bending, coupling and uncoupling of the connectors, and by two 
1-hour soaks in plasma at 4 ° and 40 ° C, respectively. Cannulas were decon- 
taminated and then processed by a peracetic acid-based liquid chemical 
sterilization system after each use/reuse. Sterilization was validated by elimi- 
nating Bacillus subtilis spores from the cannulas on each of five consecutive 
cycles. Cannulas were tested for physical changes, functional integrity, biocom- 
patibility, and in vivo performance in sheep. A cost analysis was also 
performed. Results: Sterilization was successfully achieved. Mechanical 
changes were less than 20% on all variables tudied and were undetectable by 
experienced cardiac surgeons in selective valuation. No clinically important 
differences were found between new and reused cannulas, even after nine 
simulated reuses. Reusing cannulas four times would reduce the cost per 
procedure from $53 to $19 (64%). Conclusions: Preliminary data suggest hat 
the perfusion cannulas tested can be safely and efficaciously used five times. 
Limited reuse of these disposable cannulas is technically feasible and cost- 
effective. Cannula reuse would result in a small incremental savings; however, 
with more expensive devices and higher-volume sterilization procedures, the 
savings could be considerably greater. This program provides a model for 
evaluation of other single-use medical devices for reuse. (J Thorac Cardiovasc 
Surg 1997;114:448-60) 
T he cost of disposable products has contributed markedly to the expense of surgical proceduresJ  
Limited reimbursement for procedures coupled 
with institutional cost-containment of health care 
provision has caused attention to be focused on the 
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expenditures for disposable medical products and 
the possible cost savings if such products could be 
reused. To investigate the feasibility of limited reuse 
of disposable products, we assessed our institution's 
use of disposable devices. Particular attention was 
given to high-cost and low-cost/high-volume prod- 
ucts in which a marked cost savings might be 
realized. Once candidate single-use products were 
identified for study, a program was developed to 
evaluate the safety and efficacy of reprocessing these 
devices. 
Focus was drawn quickly to the reuse of perfusion 
cannulas because cannulas are used in large num- 
bers, are of simple design, and have a history of 
reuse in our institution. Cannula reuse was a widely 
accepted practice in the early years of bypass sur- 
gery. However, when manufacturers increased the 
availability of single-use disposable cannulas, reuse 
was discontinued. Another  reason for concentrating 
on perfusion cannulas is that the prerequisites for 
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reuse of these devices, including sterilization effi- 
cacy, materials compatibility, biocompatibility, and 
device functionability, are similar to safety criteria 
for other single-use products. 
Materials and methods 
Cannula types. Venous and arterial cannulas with the 
highest volume of use in this institution were chosen for 
study. These were the Research Medical Incorporated 
(RMI, Salt Lake City, Utah) dual- and single-stage venous 
return cannulas (32F and 36F) and the 3M/Sarns (St. 
Paul, Minn.) Soft Flow 8.0 mm arterial cannula models. 
Cannula groups. Cannulas were divided into three 
main groups for testing: (1) new (unused), (2) one clinical 
use, and (3) one clinical use and nine simulated uses. 
Unused cannulas (taken directly from the manufacturer's 
original packaging) were evaluated to establish abaseline 
level. The clinically used cannulas were cleaned, decon- 
taminated, and put through a sterilization cycle after the 
initial clinical use and each subsequent simulated (re)use. 
It was estimated that five clinical uses would offer consid- 
erable cost savings for these devices. Therefore a total of 
ten uses/reuses was chosen as an end point to provide a 
margin of safety by doubling the cycle requirements. Some 
testing also evaluated the cannulas after five simulated 
reuses. 
Cannula cleaning and decontamination. After clinical 
use, the cannulas were retrieved from the operating room, 
cleaned, and decontaminated in the Surgical Processing 
Department of The Cleveland Clinic Foundation with an 
institutionally approved cleaning and decontamination 
protocol. Cleaning and decontamination consisted of the 
following steps: (1) rinsing the cannulas with tap water, (2) 
soaking, flushing, and sonicating the cannulas in a warm 
enzymatic detergent solution (Enzol, Johnson & Johnson 
Medical Inc., Arlington, Tex.), (3) rinsing them with 
deionized water, and (4) drying them with compressed air. 
Each cannula was then assigned an identification umber 
and put through a sterilization cycle. 
Simulated use. Use of the cannulas was simulated by 
flexing them end to end up to ten times, connecting the 
proximal end to the blood tubing adaptor (for RMI 
cannulas) or blood tubing (for 3M/Sarns cannulas), and 
attaching the appropriate connector tie. In addition, the 
cannulas were placed in human plasma and refrigerated 
for 1 hour at 4 ° C, which is the lowest temperature 
maintained uring bypass urgery, for that length of time. 
The cannulas then were soaked in human plasma for an 
additional hour at about 40 ° C, the highest emperature 
reached during surgery. After the plasma soak periods, 
the cannulas were rinsed with saline solution, cleaned, 
decontaminated, and put through a sterilization cycle. 
Sterilization processing. The cannulas were processed 
in the STERIS SYSTEM 1 Processor (STERIS Corpora- 
tion, Mentor, Ohio). This system has been cleared by 
the Food and Drug Administration (FDA) for the steril- 
ization of reusable immersible medical, surgical, and 
diagnostic devices. The SYSTEM 1 Processor, which is 
available at the site of care, is a table-top microprocessor- 
controlled chamber in which the liquid chemical steriliza- 
tion process is performed, controlled, and monitored. 
STERIS 20 Sterilant Concentrate was used as the 
chemical germicide for sterilization. STERIS 20 is a 
single-use sterilant registered by the U.S. Environmental 
Protection Agency, which has been developed specifically 
for use with the STERIS PROCESS. It contains the active 
sporicidal ingredient peracetic acid with a proprietary 
chemical buffering, anticorrosive formulation. STERIS 20 
is mixed automatically with water that has been filter- 
sterilized by the processor to form a solution. This solu- 
tion flows and mixes in the processor's chamber, thereby 
coming into contact with all accessible xternal and inter- 
nal surfaces of the cannulas. The sterilization phase of the 
process lasts 12 minutes and is followed by four sterile 
water rinses to free the devices of sterilant residues. The 
entire process is completed in about 30 minutes. 
Up to four cannulas per cycle were processed in the 
STERIS General Processing Container. The cannulas 
were placed on a rack in the STERIS General Processing 
Container with the large lumen end elevated. 
Validation of sterilization. Individual cannulas were 
inoculated with a Bacillus subtilis (ATCC No. 19659) 
spore suspension of at least 107 colony-forming units (cfu) 
per milliliter by means of a syringe filled with this spore 
solution. Bacillus subtilis spores were chosen as the test 
organisms because they are highly resistant o the steril- 
ant. Harvesting was performed after processing by swab- 
bing selected sites on the body, ends, and lumen of the 
cannulas. After swabbing, the lumen was eluted with 10 ml 
of sterile water, which was collected in a test tube con- 
taining 10 ml double-strength tryptic soy broth; the result- 
ing mixture was cultured. The swab and elution samples in 
tryptic soy broth were cultured for 7 days at 37 ° C. For 
sterilization to be considered valid, the absence of culture 
growth in all samples was required for five consecutive 
sterilization cycles. A recoverable bioburden evaluation 
was also performed to determine the level of inoculum 
adhering to the cannulas. Recoverable bioburden samples 
were quantified by plating them on tryptic soy agar for 48 
hours at 37 ° C. In addition, a positive control cycle (in 
which the sterilant's active ingredient, peracetic acid, is 
omitted) was run to demonstrate hat the acid is required 
for sporicidal activity. This was demonstrated byevaluat- 
ing the presence of spores adhering to the cannula test 
sites by means of swabbing and elution techniques after 
the control cycle. 
Materials and function testing. The effects of repro- 
cessing on the functional properties and characteristics of
the eannulas were tested. Materials were evaluated by 
assessing their physical appearance, color, tactile proper- 
ties, hardness, and dimensional changes after simulated 
use and sterilization. Two function tests were also per- 
formed: (1) a cantilever bend test 2 (which measures 
cannula displacement as a function of a hanging weight) 
to assess the flexibility and bending strength of the 
cannula's body and tip and (2) a tensile test 3 to assess the 
integrity of the joints and bonds along its length. Because 
the distal tip of the 3M/Sarns arterial cannula is connected 
to the body by struts, these cannulas were evaluated 
during mechanical shear conditions as well. All tensile and 
shear tests were performed on a Bionix Test System 
(model 858; MTS Systems Corp., Minneapolis, Minn.) 
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Fig. 1. Mechanical properties obtained from tensile tests. 
The diagram is a representative force-displacement graph 
obtained from a tensile test. The diagram illustrates the 
mechanical properties determined from the force-dis- 
placement curve. The mechanical properties are as fol- 
lows: 1, Tensile stiffness: The slope of the linear (elastic) 
portion of the force-displacement curve. 2, Yield strength: 
The point along the force-displacement curve that desig- 
nates the transition from elastic (recoverable) to plastic 
(permanent) deformation by means of the 0.02% strain 
offset method. The intersection of the force-displacement 
curve and the dashed line (the o~set line) designates the 
transition point. 3, Ultimate tensile strength: The maxi- 
mum load/force experienced uring the tensile test. 4, 
Elongation-at-break: The length to which the specimen is 
elongated at the point of failure. 5, Energy-to-break: The 
total area under the force-displacement curve. 
with a Test Star Controller (model 490) and Test 
Ware-SX Applications Software (MTS Systems). 
Tensile testing of the cannulas resulted in force-dis- 
placement curves (Fig. 1) from which five mechanical 
properties were measured: tensile stiffness, yield strength, 
ultimate tensile strength, elongation-at-break, nd energy- 
to-break. Tensile stiffness is the ratio of the applied force 
to the displacement and is a measure of the material's 
resistance to elastic (recoverable) deformation. Tensile 
stiffness was the only property that could be measured 
when testing was limited to below the device's yield point. 
Energy-to-break is the amount of energy (area under the 
force-displacement curve) required to cause a material to 
fail or break. Analogous properties were also obtained 
from the torque-displacement curves generated from the 
mechanical shear tests. The cantilever bend test displace- 
ment data and the mechanical properties described were 
analyzed by means of unpaired Student's t tests to com- 
pare the new and used cannulas. All tests were two tailed 
and c~ was set at 0.05. 
Bioeompatibility esting. Various tests were conducted 
to assess the biocompatibility of the cannulas. These tests 
included residue analysis (both cannula and sterilant), 
cytotoxicity, hemolysis, muscle implant, pyrogen/endo- 
toxin analysis, and toxicity (systemic and intracutaneous). 
All of the testing except for the sterilant residue analysis 
was performed by an outside independent laboratory 
(NAmSA, Northwood, Ohio). Biocompatibility testing 
was performed on both RMI dual-stage venous and 
3M/Sarns arterial perfusion cannulas. Unless otherwise 
noted, all of the test cannulas were clinically used once 
and then underwent nine simulated uses including eleven 
or twelve sterilization cycles. The RMI single-stage venous 
cannula model was not evaluated because its materials are 
identical to those of the dual-stage cannula. 
To evaluate cannula extractables, extractions with U.S. 
Pharmacopeia (USP) purified water at 37 ° C for 24 hours 
were carried out on unused cannulas that were processed 
once and then compared with new cannula residue ex- 
tracts. Each extract was dried at 100 °C for 24 hours. A 
portion of the residue was dissolved in tetrahydrofuran. 
The solution was applied to a potassium bromide disc and 
the solvent was allowed to evaporate. Infrared analysis 
was performed on the resulting film to assess organic 
extractions. 
The two cannula models were also extracted separately 
with 0.1N sodium hydroxide and 0.1N hydrochloric acid so 
that select sterilant components could be analyzed by two 
methods: (1) inductively coupled plasma emission spec- 
trophotometry for elemental analyses and (2) ultraviolet 
spectrophotometry for an organic anticorrosive formula- 
tion agent. New, unused cannulas were used as controls. 
After the final sterilization cycle, test strips for hydrogen 
peroxide (EM Quant peroxide test strips, EM Science, 
Gibbstown, N.J.) and peracetic acid (Merckoquant per- 
acetic acid strips, EM Science) were used to detect 
residues of these chemicals from the sterilization process. 
Cytotoxicity testing of unused RMI dual-stage venous 
cannulas (processed once) and clinically used 3M/Sarns 
arterial cannulas (nine simulated uses and processed 12 
times) was performed by means of the minimum essential 
medium elution method. The cannulas were extracted 
with 5% minimum esential medium solution at 37 ° C for 
24 hours. A monolayer of L-929 mouse fibroblast cells 
(grown to confluency) was exposed to the extract, and 
after incubation the cells were evaluated for changes in 
cell shape. 
In vitro hemolysis testing consisted of extracting the 
cannulas with a 0.9% sodium chloride solution at 70 ° C for 
24 hours. Rabbit blood collected in ethylenediaminetet- 
raacetic acid was added to a portion of the extract solution 
at room temperature. This solution was then heated to 
37 ° C in a constant temperature bath for 1 hour and the 
percent of hemolysis was determined spectrophotometri- 
cally. 
In the USP muscle implantation test, slivers of the test 
cannulas were implanted into the paravertebral muscle of 
New Zealand White albino rabbits for 7 days. After 
excision, the tissue surrounding each implant was macro- 
scopically evaluated for evidence of encapsulation or 
adverse reaction. Tire implant sites were also histologi- 
cally processed and microscopically evaluated. 
Pyrogenicity testing involved assessing the presence of 
endotoxin using the Limulus amebocyte lysate gel test. 
For the USP systemic extract oxicity studied in mice and 
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Fig. 2. Materials evaluation--Dimensions, RMI dual-stage venous cannula. 
Table I. Sterilization validation data for cannulas challenged with Bacilus subtilis spore suspensions 
Sterilization cycle Positive control cycle Recoverable bioburden 
Cannula model (No. sites sterile~No, tested) (No. sites not sterile~No, tested) (range: ×103 cfu/device) 
RMI dua] stage 
Clinical use* (n = 5) 100/100 20/20 
Simulated uset (n = 5) 100/100 20/20 
RMI single stage 
Clinical[ use* (n = 5) 75/75 15/15 
Simulated uset (n - 5) 75/75 15/15 
3M/Sarns 
Clinical use* (n = 5) 125/125 25/25 
Simulated uset (n = 5) 125/125 25/25 
Total (n = 30) 600/600 120/120 
3.84 to >-68.1 
31.8 to >-84.3 
7.17 to 15.3 
12.3 to >-41.8 
11.2 to -->42.0 
6.90 to 16.8 
Overall range of 
recoverable bioburden: 
3.84 × 103 to ->8.43 × 104 cfu/device 
*Cannulas with one clinical use (one sterilization cycle). 
tCannulas with one clinical use and nine simulated uses (10 sterilization cycles). 
the USP intracutaneous extract toxicity studied in rabbits, 
extracts of both saline solution and cottonseed oil from 
each of the two cannula models were studied. 
In vivo testing. To assess the overall effect of multiple 
reprocessing and to allow for a qualitative evaluation by a 
surgeon, we analyzed RMI single-stage venous perfusion 
cannulas during surgical use. Two new cannulas and three 
used cannulas (clinically used once and processed four 
times without simulated use = five total sterilization 
cycles) were used in sheep undergoing cardiac valve 
replacement as part of an animal research protocol. All 
animals used in this study received humane care in 
compliance with the "Principles of Laboratory Animal 
Care" formulated by the National Society for Medical 
Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the Institute of Labo- 
ratory Animal Resources and published by the National 
Institutes of Health (NIH Publication No. 86-23, revised 
1985). 
Results 
Validity of sterilization. All clinically used and 
simulated-use cannulas that were inoculated with 
Bacillus subtilis spores showed no signs of the test 
organism after sterilization (Table I). In the positive 
control evaluation of the sterilization system without 
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Fig. 3. Materials evaluation--Dimensions, RMI single-stage venous cannula. 
the sporicidal agent peracetic acid, all sites showed 
growth. This result demonstrates that neither the 
fluid action during the cycle, the sterilant compo- 
nents (other than the peracetic acid), nor the suc- 
cessive sterile water rinses were responsible for the 
sporicidal activity. 
In studies assessing the inoculated sites, recovery 
of Bacillus subtilis spores ranged from 3.84 × 103 to 
8.43 × 104 cfu or more per device (Table I). 
However, inasmuch as only discrete sites on the 
cannulas were recovered for bioburden, as opposed 
to evaluating the entire surface of the cannula, the 
recovery results underestimate he total level of 
inoculation. 
After clinical use but before cleaning or steriliza- 
tion, clinically used cannulas (n = 10) were evalu- 
ated for contamination. Growth was found on only 
two of the cannulas. The vegetative bacteria identi- 
fied (presumptive Staphylococcus epidermidis) on 
these cannulas are significantly less resistant to the 
sterilant than the Bacillus subtilis spores used in this 
study. Furthermore, the concentration of the vege- 
tative bacteria was very low (<20 cfu per device) 
compared with the spore contamination levels on 
the cannulas measured in the recoverable bioburden 
evaluations. 
Materials and function testing. After reprocess- 
ing, the appearance of the reused cannulas was 
not noticeably different from that of new, unused 
cannulas. Slight yellowing in the RMI dual-stage 
cannulas and in the 3M/Sarns cannulas in the 
simulated-use group was noticed. The discolora- 
tion, which was a change in the material tint and 
not its opacity, has no known effect on the clinical 
properties of the cannulas. Localized arker yellowing 
was noted in some of the cannulas and appeared to be 
associated with imperfections in the material; this 
might be related to variability in the manufacturing 
process. No changes in texture occurred after repro- 
cessing. 
Variable amounts of surface scoring at the prox- 
imal end of the cannulas, where the plastic connec- 
tors are inserted, were noted on all RMI cannulas. 
This physical damage, which increased with the 
number of (re)uses, was related to the connector 
design and could be eliminated with more careful 
handling of the cannulas during insertion and re- 
moval of the connector or by using a connector with 
a smoother hose barb profile. Scoring did not occur 
on the 3M/Sarns cannulas because the connector is 
bonded to the cannula body and no assembly is 
required between the connector and cannula. 
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Fig. 5. Function testing--22 ° C, RMI dual-stage venous cannula. NS, Not significant. *Controls (new 
cannulas), n = 5. 
Slight dimensional changes were found at some 
sites on the three cannula models studied (Figs. 2 to 
4). However, evaluations by a cardiac surgeon indi- 
cated that none of the changes were clinically im- 
portant. For example, the internal diameter of the 
connector end on the RMI cannula models (which 
requires tile insertion of a connector) did not change 
markedly. Thus the cannula's ability to be properly 
connected to the blood tubing and provide a leak-free 
conduit for blood flow was not impaired. Furthermore, 
durometer (hardness) assessments of the cannulas 
showed no statistically significant changes. 
A statistically significant decrease in bending stiff- 
ness (resulting in an increase in displacement) was 
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found in the body of the RMI dual-stage cannulas, 
whereas a nonsignificant decrease in stiffness was 
found in the tip (Fig. 5). An increase in the body and 
tip-bending stiffness was found to be nonsignificant 
for the RMI single-stage cannulas (Fig. 6). Bending 
stiffness of the 3M/Sarns cannulas howed a statis- 
tically significant yet small increase as compared 
with the new (unused) cannulas for both the body 
and tip (Fig. 7). All mean changes in the three 
cannulas were 20% or less and virtually undetect- 
able by manual manipulations. Tensile stiffness of 
the body of the RMI dual-stage venous cannulas 
increased by less than 15%, a change that was 
statistically significant (Fig. 5). The tensile stiffness 
of the body of the RMI single-stage venous cannulas 
showed an increase of less than 10%, which was not 
a statistically significant change. Changes in tensile 
stiffness and other tensile properties in the body and 
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tip of the reprocessed 3M/Sarns cannulas were less 
than 10% and not statistically significant (Fig. 8). 
After reviewing the new and reprocessed cannulas 
with a cardiac surgeon, we deemed a change in each 
test parameter of less than 20% to be clinically 
acceptable. 
Because of the unique tip design of the 3M/Sarns 
arterial cannulas that incorporates struts, the tor- 
sional performance of this design was also evaluated 
in a mechanical shear test. As with bending stiffness 
and tensile properties, torsional properties howed 
changes of less than 20% from the controls (Fig. 9). 
Although statistically significant changes were 
noted in some cases, the changes were virtually 
undetectable by qualitative evaluation (manual 
manipulation) and, in the opinions of the consult- 
ing cardiac surgeons, were not considered clini- 
cally significant. All changes in the cannulas, after 
clinical or simulated use, whether statistically 
significant or not, were less than 20% from the 
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Table II. Summary of materials and functional testing for RMI dual-stage venous perfusion cannulas at room 
temperature (22 ° C) 
Simulated-use 
Unused cannulas cannulas p Value* 
Test type Property (mean [+- SD]) (mean {+- SD]) (% change) 
Materials Appearance Control Scoring at proximal end - -  
Color Control Slight yellowing - -  
Tactile/texture Control No apparent difference - -  
Bending n = 5 n = 10 
Tensile 
Bending stiffness (in) 
Body 2.71 (0.15) 3.20 (0.20) <0.001 ( -15%)  
Tip 0.14 (0.02) 0.17 (0.04) NS ( -21%)  
Tensile stiffness (N/mm) n = 5 n = 10 
Body 1.84 (0.14) 2.07 (0.11) 0.004 (+13%) 
SD, Standard eviation; NS, nonsignificant (p > 0.05). 
*Student's two-tailed unpaired t test; a = 0.05. 
Table III. Summary of materials and functional testing for RMI single-stage venous perfusion cannulas at 
room temperature (22 ° C) 
Simulated-use 
Unused cannulas cannulas p Value* 
Test type Property (mean [+_ SD]) (mean [+_ SD]) (% change) 
Materials Appearance Control Scoring at proximal end - -  
Color Control No apparent difference - -  
Tactile/texture Control No apparent difference - -  
Bending n = 5 n = 10 
Tensile 
Bending stiffness (in) 
Body 4.46 (0.22) 4.23 (0.21) NS (+9%) 
Tip 0.30 (0.04) 0.27 (0.04) NS (+ 10%) 
Tensile stiffness (N/ram) n = 5 n = 10 
Body 0.92 (0.10) 0.99 (0.21) NS (+8%) 
SD, Standard eviation; NS, nonsignificant (p > 0.05). 
*Student's two-tailed unpaired t test; c~ = 0.05. 
control (new) values. Tables II to IV compare the 
materials and functional test data for all three 
cannula models. 
Because the cannulas in clinical use may be 
subjected to temperatures ranging from 4 ° to 40 ° C, 
a specialized study of the 3M/Sarns arterial cannulas 
was carried out to evaluate the bending stiffness, 
tensile stiffness, and durometer properties at these 
extreme temperatures. No statistically significant 
differences were noted between the control (new) 
devices and reprocessed cannulas at 4 ° and 40°C 
(Fig. 10). 
Bioeompatibility esting. Infrared analysis of the 
RMI dual-stage venous and 3M/Sarns arterial can- 
nula extracts howed no important qualitative dif- 
ferences in extractions between unused and simu- 
lated-use cannulas. The individual peaks in the 
infrared scans were virtually identical and unable to 
be identified with the available references of the 
independent laboratory. These results would indi- 
cate that the sterilization process does not create 
any additional leachates from the product. The 
extractable residue (which was greater from the 
control devices) appears to come directly from the 
cannula and is not a result of the sterilization 
process. The sodium hydroxide and hydrochloric 
acid extracts also did not differ significantly from 
controls. The studies indicate no significant reten- 
tion or accumulation of sterilant components in 
the cannulas, even after 11 sterilization cycles. 
Residual hydrogen peroxide and peracetic acid 
levels within the sterilization processor after ster- 
ilization were no more than 5 ppm for peracetic 
acid and no more than 0.5 ppm for peroxide. 
These low levels indicate that the sterilant was 
adequately removed from the processor by the 
sterile water rinses. 
The cytotoxicity test is considered to be highly 
sensitive and, in most cases, is more sensitive than 
the muscle implantation test. 4 The reprocessed RMI 
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Table IV. Summary of materials and functional testing for 3M/Sarns arterial perfusion cannulas at room 
temperature (22 ° C) 
Simulated-use 
Unused cannulas cannulas p Value* 
Test type Property (mean [+ SD]) (mean [+_ SDl) (% change) 
Materials Appearance Control No apparent difference - -  
Color Control Slight yellowing - -  
Tactile/texture Control No apparent difference - -  
n =6 n=5 
Bending 
Tensile 
Shear (tip only) 
Hardness 
Wire-reinforced body 68.0 (4.3) 70.6 (2.6) NS (+4%) 
Nonreinforced body 51.8 (2.5) 50.6 (5.3) NS (-2%) 
n=6 n=10 
Bending stiffness (in) 
Body 3.22 (0.08) 3.04 (0.17) 0.03 (+5%) 
Tip 0.86 (0.06) 0.80 (0.05) 0.04 (+ 10%) 
n=5 n=10 
Tensile stiffness (N/ram) 
Body 
Tip 
Tensile yield strength (N) 
Ultimate tensile strength (N) 
Elongation-at-break (mm) 
Energy-to-break (m J) 
Torsional stiffness (N-mm/deg) 
Torsional yield strength (N-mm) 
Ult. torsional strength (N-ram) 
Angle-at-yield ( eg) 
Energy-to-yield (mJ-deg) 
1.79 (0.12) 1.80 (0.21) NS (+<1%) 
1005.9 (188.8) 1043.5 (82.3) NS (+4%) 
219.0 (28.4) 207.1 (17.9) NS (-5%) 
262.8 (24.1) 245.3 (11.9) NS (-6%) 
0.90 (0.07) 0.96 (0.05) NS (+7%) 
179.3 (8.6) 172.2 (15.2) NS (-4%) 
n=9 n=3 
37.1 (3.5) 40.4 (4.1) NS (+9%) 
170.5 (33.7) 165.1 (18.2) NS (-3%) 
268.4 (43.1) 298.9 (57.6) NS (+11%) 
5.60 (1.00) 4.97 (1.24) NS (-11%) 
590.6 (275.9) 480.8 (227.6) NS (-18%) 
SD, Standard deviation; NS, nonsignificant (p > 0.05). 
*Student's wo-tailed unpaired t test; c~ = 0.05. 
dual-stage venous and 3M/Sarns arterial cannulas 
did not meet the USP requirements for in vitro 
cytotoxicity. However, the USP (in vivo) muscle 
implantation tests showed no significant macro- 
scopic reactions to the test materials when com- 
pared with a control implant (USP negative materi- 
al). Microscopic examination of the implants 
resulted in a material rating of nonirritant to slight 
irritant. Therefore, although this discrepancy in the 
results exists, the positive cytotoxicity est results can 
generally be dismissed if the balance of in vivo 
testing proves acceptable. 
In vitro hemolysis testing on the two cannula 
models howed that hemolysis was below 0.5%; thus 
the cannulas were considered to be nonhemolytic. 
Bacterial endotoxins in the extracts were less than 
0.125 EU/ml (endotoxin units per milliliter) for the 
RMI dual-stage cannulas and less than 0.5 EU/ml 
for the 3M/Sarns arterial cannulas. Hence the pro- 
cessed cannulas met the requirements of the FDA 
and USP for medical devices (<-0.5 EU/ml) and are 
considered nonpyrogenic. Last, systemic toxicity and 
intracutaneous toxicity studies howed that the ex- 
tracts were nonirritants. Therefore the cannulas met 
USP requirements and are considered nontoxic. 
In vivo testing. Cardiac valve replacement exper- 
iments in sheep using the RMI single-stage venous 
perfusion cannulas howed no differences in device 
use or performance (insertion, handling, function, 
and removal) between the new and reprocessed 
(clinically used once and processed four times with- 
out simulated use) cannulas. In these studies, the 
coronary bypass times ranged from 71 to 159 min- 
utes, pump temperatures ranged from 30 ° to 40 ° C, 
and heparin infusion during bypass ranged from 
11,000 units to 17,000 units. No blood component 
deposits or surface clots were detected on the 
cannulas. In addition, thromboembolism did not 
occur in the pulmonary arteries, and the infection 
rate in the test animals was the same as that in 
control animals. Infection, which was determined by 
a temperature ise of more than 40 ° C with a normal 
white blood cell count, was noted in one test case 
and in one control case. Evaluation by the cardiac 
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surgeon showed that performance of the repro- 
cessed cannulas is comparable with that of new 
ones. 
Cost minimization analysis. A basic cost minimi- 
zation analysis was undertaken to determine 
whether it would be economically feasible to use 
perfusion cannulas five times (once when new and 
four additional times with required reprocessing), 
assuming that safety and efficacy after each use 
remained equal to that of new cannulas. Total and 
incremental costs of reusing these perfusion cannu- 
las four times after their initial use were calculated. 
To provide a complete cannula set per surgical case 
(including multiple sizes), the STERIS General 
Processing Container can be modified to accommo- 
date five cannulas. It is assumed that all cannulas 
can be reprocessed four times and that five cannulas 
can be reprocessed uring a single sterilization 
cycle. 
Costs for a single sterilization cycle include the 
sterilant ($5), consumable supplies ($2), and capital 
equipment ($3). Capital costs are based on an initial 
cost of $16,200 for a STERIS SYSTEM 1 amortized 
over 5 years (assuming that the system would pro- 
vide 1000 cycles each year). The cost for a single 
sterilization cycle would, therefore, be $10. When 
processing five cannulas per cycle, the cost of ster- 
ilizing a single cannula would be $2 (all cost esti- 
mates are from STERIS Corporation). To this fig- 
ure must be added a reprocessing cost ($1.77), 
which is based on labor costs of $10 per hour (data 
provided by The Cleveland Clinic Foundation). 
Therefore the incremental cost of reusing a cannula 
equals $3.77. In contrast, the cost of a new cannula 
is $20 (sources: Research Medical Inc. and 3M/ 
Sarns Corporation). 
The annual total and incremental costs per pro- 
cedure for using new and reused cannulas are 
provided in Table V. By reusing cannulas, the 
incremental cost per procedure is $18.64, which is 
a 65% savings over the current cost of $53.13. If 
implemented, a program to reuse perfusion can- 
hulas would save the institution $110,364 each 
year. 
Discussion 
Many of the currently disposable medical devices 
now being considered for reuse (i.e., hemodialyzers, 
perfusion cannulas) were originally designed for 
reuse. With the increasing availability of mass pro- 
duction manufacturing techniques and less expen- 
sive materials, these devices were made and sold as 
disposables. The durability of many disposable 
products, particularly high-cost and/or high-volume 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 114, Number 3 
Bloom et al. 4 5 9 
products, has prompted studies into the safety and 
efficacy of their reuse. 
Several studies have attempted to address the 
many issues surrounding the reuse of disposable 
devices. In a 1993 study on the reuse of perfusion 
cannulas, ~; cannulas were rinsed free of blood, pro- 
cessed in a washer-sterilizer at 140 ° C for 30 min- 
utes, evaluated for breaks and defects, wrapped, 
sterilized in ethylene oxide for 3 hours, and aerated 
for 12 hours before clinical use. This study con- 
tained no discussion of safety and etficacy of the 
reprocessing methods, although recycling of cannu- 
las had been used as a method of cost savings for 
many years. Other studies of disposable cardiovas- 
cular catheters eused for catheterization a d angio- 
plasty generally reported clinical outcomes only, 6-s 
although, in some studies, safety and functional 
evaluations on devices have been carried out to a 
limited degree. 9'10 
In contrast o past studies, the current study 
presents a comprehensive approach to evaluating 
reuse of disposable medical devices. Perfusion 
cannulas were selected for investigation and used 
to create a model reprocessing program because 
these cannulas were at one time routinely repro- 
cessed in the United States and because they have 
a simple design. The following testing was per- 
formed on the perfusion cannulas most frequently 
used in t]he institution: sterilization efficacy, de- 
vice materials and function assessments, biocom- 
patibility assessments, and an animal study. The 
liquid chemical sterilization system used in this 
study was chosen for its ability to sterilize temper- 
ature-sensitive products and provide rapid turn- 
around times (about 30 minutes after cleaning and 
decontamination). 
With bioburden levels higher than those expected 
in clinical use, and for an inoculum of Bacillus 
subtilis spores, an organism highly resistant to ster- 
ilization, cannula sterility after reprocessing was 
achieved in every case. The level of recoverable 
bioburden on the cannulas was noted to be in the 
range of 103 to 10 4 cfu per device. This level of 
recoverab]le bioburden does not meet the current 
American Society for Testing and Materials require- 
ment of 10 6 cfu per device, which was established 
after the cannula sterilization testing was com- 
pleted, n In a separate study using the same steril- 
ization system, RMI dual-stage venous return can- 
nulas were soiled with a Bacillus subtilis (107 c fu /ml )  
spore suspension consisting of 5% bovine whole 
blood in physiologic saline solution (0.9% NaC1). 12 
Table V. Cost minimization analys& comparing the 
annual costs of new perfusion cannulas to the costs 
of perfusion cannulas used five times* 
Savings 
Without With with cannula 
reuse  reuse  reuse  
Number bought/year 8500 1700 6800 
Cost of first use $20.00 $20.00 
Cost of second use - -  $3.77t 
Cost of third use - -  $3.77 
Cost of fourth use - -  $3.77 
Cost of fifth use - -  $3.77 
Total cost/year $170,000 $59,636 $110,364 
Number of procedures/year 3,200 3,200 
Incremental cost/procedure $53.13 $18.64 $34.49 
*Initial use (when new) and four additional reuses 
resterilization). 
fSee text for derivation of unit cost of sterilization. 
(each involving 
The devices were inoculated by being totally sub- 
merged in the spore suspension and then air dried 
for at least 30 minutes. The level of inoculation 
recovered on the devices ranged from 0.98 × 10 6 to 
2.5 N 10 6 cfu or more per device. There was no 
cleaning or decontamination f the devices after 
inoculation and before the sterilization cycle. After 
each cycle, all test sites (n = 60; three cannulas, four 
sites per cannula, five process cycles per cannula) 
showed the absence of the test organism, which 
indicates that soiling with a high level of inoculum 
containing whole blood and salt has no effect on the 
ability of the system to sterilize the cannulas. One 
reason for the large discrepancy in the bioburden 
recoveries between the two studies may be that 
different inoculation techniques were used. In this 
study, the device was inoculated with the use of a 
syringe by partially wetting the cannula surfaces with 
the spore suspension, whereas in the blood/salt 
study the device was completely immersed in the 
inoculum. 
The cannulas howed no physical or mechanical 
changes that would appear to affect their use or 
function. Where defects were noted, or where scor- 
ing occurred, visual inspection by trained staff would 
be sufficient to eliminate these cannulas from fur- 
ther use. 
Analysis of cannula sterilant extracts found no 
significant differences between ew and reprocessed 
cannulas. The positive in vitro cytotoxicity results 
may only reflect the high sensitivity of this test 
method. 4 The fact that the cannulas passed the 
other biocompatibility ests, including the muscle 
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implantation test, and that no adverse reactions 
were observed in the animal model (one of the 
cannula models evaluated), showed that the repro- 
cessed cannulas are safe. 
The results of this testing suggest that a clinical 
trial be designed and carried out to assess the 
clinical utility and overall economic impact of 
reuse of perfusion cannulas. As reuse is expanded 
to other products after careful laboratory-based 
research and clinical trials, the savings in total 
health care costs should be substantial. With the 
reduction of health care reimbursement, remov- 
ing costs from the system is the only way in which 
institutions can continue to provide the highest 
quality medical care to all patients. The successful 
reuse of traditionally disposable medical products 
and devices must be associated with the highest 
quality of laboratory-based research and a willing- 
ness of regulatory bodies to review the scientific 
data objectively and rigorously and, if positive, to 
approve clinical trials. 
The statistical analysis was performed by Michelle 
Secic, MS. We thank Tom Lang for editorial assistance in 
the preparation of this manuscript. 
Note 
This feasibility study was undertaken to determine 
whether a more substantial study of resterilization of 
disposable devices would be reasonable to pursue. The 
study was not intended to demonstrate the safety and 
effectiveness of reusing any specific device or resterilizing 
with the sterilization process in the study. Neither the 
devices tested nor the sterilization process used to rester- 
ilize them are cleared by the U.S. Food and Drug Admin- 
istration for reuse or resterilization of devices labeled for 
single use. 
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